Publications

This post hoc analysis of 2 randomised controlled trials (RCTs) AMBITION and ADACTA found that tocilizumab monotherapy results in substantial and clinically meaningful improvements in patient-reported outcomes (PROs) over 24 weeks.PROs assessed included patient global assessment (PtGA), pain, HAQ-DI, Functional Assessment of Chronic Illness Therapy (FACIT-F) and Short-Form-36 (SF-36) physical component summary (PCS) and mental component summary (MCS) and eight domain scores.Tocilizumab (TCZ) monotherapy was more effective than methotrexate and adalimumab monotherapies in improving PROs. Furthermore, patients who received TCZ reported higher mean scores across all SF-36 domains that more closely approached age and gender-matched normative values. Consistent with these improvements, significantly greater improvements in CDAI were seen with TCZ versus methotrexate or adalimumab.Side effects were not reported within this paper.These data support the finding that TCZ may make it possible for patients with RA to achieve PRO scores that closely resemble those reported by healthy populations.